A skin cancer diagnosis can be difficult to hear, but the problem is not necessarily difficult to treat. Modern technologies have made the safe and effective destruction of non-melanoma cancer cells more readily available—and comfortable. For patients dealing with basal cell carcinoma or squamous cell carcinoma, Charleston's Germain Dermatology offers image-guided superficial radiotherapy with the Sensus Healthcare SRT-100 Vision™.
The Sensus Healthcare SRT-100 Vision™ is an FDA-cleared device that uses gentle x-rays to kill cancer cells in the superficial layers of the skin. In addition to treating basal and squamous cell carcinoma, it also works on non-malignant cells that cause raised scars known as keloids.
Schedule an appointment to discuss image-guided superficial radiotherapy with the Sensus Healthcare SRT-100 Vision™ for keloids or basal and squamous cell carcinoma in Charleston, SC. Contact Germain Dermatology to learn more by calling (843) 881–4440 or send a message online.
"SRT" stands for "superficial radiotherapy," indicating that the energy delivered by the device is not the same as traditional cancer treatments. The SRT-100 Vision™ device limits its energy delivery to the surface of the skin, in addition to the imaging component with daily ultrasound ensuring appropriate clinical response and progress. That means it impacts only a shallow layer of tissue, as opposed to organs and systems found deeper in the body.
Because of its intended lack of depth, SRT-100 Vision™ is for treating skin cancers that do not typically extend beyond the surface. Since melanoma is known to spread rapidly, superficial radiotherapy is appropriate for basal cell carcinoma and squamous cell carcinoma.
While the sessions are painless, patients having their basal or squamous cell carcinoma treated will notice that the target area will become pink after several treatments. A crust or scaly patch may develop. In areas where hair is present, patients can expect some localized hair loss, though the follicles will grow new hairs after the course of radiation sessions is over.
SRT-100 Vision™ treatments are highly effective and comparable to Mohs surgery, but are not surgical and so leave no scar.
Basal cell carcinoma is the most common form of skin cancer, developing in the specialized cells that produce new skin cells at the base of the surface. Squamous cell carcinoma is less common and a bit more aggressive, but develops higher in the surface later. While many elements can contribute to a person's risk of developing cancer, basal and squamous cell carcinoma are both related to cumulative sun exposure.
Basal and squamous cell carcinomas can appear as scaly patches, lesions, or moles. Early detection and treatment of skin cancer is key, especially since diagnosis can reveal the type and stage of a cancer. Melanoma, while less common than either basal or squamous cell carcinoma, is known for its potential for rapidly spreading to other systems. SRT-100 Vision™ is not an appropriate treatment for melanoma.
Patients with basal or squamous cell carcinomas may also consider Mohs surgery, a specialized technique that involves removing thin layers of tissue until no cancer cells can be detected in the treatment area. Dr. Marguerite Germain, and the Germain Dermatology team are devoted to providing each skin cancer patient with an effective and safe treatment that best suits their unique condition.